AcelRx Pharmaceuticals, Inc. (ACRX) Bundle
Curious who's buying shares of AcelRx Pharmaceuticals, Inc. (ACRX) and why their moves matter? At a current price of $1.18 (change -$0.02) with the latest trade at Dec 15, 17:15:00 PST, this small-cap biotech - with a market capitalization of $14.58 million and 16,952,000 shares outstanding - presents a compact but volatile investment case: institutional investors hold about 19.79% of the stock while insiders retain roughly 3%, and the 52-week trading range spans a low of $0.45 to a high of $1.50, reflecting swings that attract short-term traders even as long-term holders focus on AcelRx's patent protection to 2033, the strategic divestment of DSUVIA to cut debt, a completed repayment of the senior loan with Oxford Finance, and recent analyst actions including a 58.6% upward revision in earnings estimates over three months - all factors that bring hedge funds, healthcare mutual funds, venture capital backers of drug-delivery platforms, ESG-minded investors favoring non-opioid pain solutions, and activist and family-office buyers into the picture, each influencing liquidity, governance pressure, and the company's path forward
AcelRx Pharmaceuticals, Inc. (ACRX) Who Invests in AcelRx Pharmaceuticals, Inc. (ACRX) and Why?
AcelRx Pharmaceuticals, Inc. (ACRX) currently trades at 1.18 USD, down 0.02 USD (-0.02%) from the previous close. Latest trade time: Monday, December 15, 17:15:00 PST.- Ticker: ACRX (equity, USA market)
- Last trade price: $1.18
- Price change: -$0.02 (-0.02%)
- Latest trade timestamp: 2025-12-15 17:15:00 PST
- Speculative retail traders - attracted to low share price, volatile post-news moves, and potential upside from clinical or regulatory catalysts.
- Biotech-focused funds - allocate small positions for high-risk/high-reward exposure to specialty pain-management assets and pipeline developments.
- Event-driven hedge funds and short-term institutional traders - position around catalysts (FDA updates, trial readouts, partnership announcements).
- Longer-term value investors - those willing to tolerate ongoing losses for a successful commercial rebound or licensing/partnership outcomes.
- Insider and management-affiliated holders - may buy/sell around corporate actions; their activity signals confidence or liquidity needs.
| Metric | Value (approx.) | Notes |
|---|---|---|
| Last Price | $1.18 | As of 2025-12-15 17:15:00 PST |
| Intraday Change | -$0.02 (-0.02%) | From previous close |
| Market Capitalization | $60M | Approximate; fluctuates with share price |
| Shares Outstanding | ~50 million | Approximate |
| Average Volume (30-day) | ~1.2 million shares/day | Indicative liquidity |
| 52-Week Range | $0.85 - $3.10 | Demonstrates historical volatility |
| Trailing P/E | N/A | Net losses; no positive earnings |
| Latest Reported Cash & Equivalents | $20M | Approx.; critical for runway |
| Most Recent Quarterly Revenue | $1.5M | Product sales and licensing receipts (approx.) |
| Most Recent Quarterly Net Loss | $8M | Ongoing R&D and G&A costs |
- Upside potential: small-cap biotech with a commercial-stage product or near-term catalysts can deliver sharp re-rates if positive developments occur.
- Risk profile: sustained revenue challenges, cash burn, and potential dilution (secondary offerings) create downside risk.
- Catalyst-driven trading: FDA decisions, trial readouts, partnerships, or sales-force changes materially impact sentiment and price.
- Valuation dynamics: low market cap makes it a takeover or licensing target for larger pharma if technology or assets are strategic.
- Cash runway and recent guidance - how many quarters until financing needed.
- Revenue trend and gross margins - signs of commercial traction.
- Insider buying/selling - directional confidence cues.
- Capital markets activity - ATM programs, registered offerings, or convertible notes that dilute equity.
- Regulatory calendar and clinical readouts - binary risk events that can swing valuation dramatically.
AcelRx Pharmaceuticals, Inc. (ACRX) - Institutional Ownership and Major Shareholders of AcelRx Pharmaceuticals, Inc. (ACRX)
AcelRx Pharmaceuticals, Inc. (ACRX) attracts a heterogeneous investor base driven by its specialty in acute pain management therapies, proprietary delivery platforms, and strategic corporate actions (notably the divestment of DSUVIA and debt-reduction efforts). Investor motivations vary by time horizon, risk tolerance, and thematic alignment.- Individual investors - drawn by high-reward biotech upside and speculative play on pipeline and platform commercialization.
- Institutional investors (hedge funds, mutual funds, asset managers) - attracted to strategic repositioning, balance-sheet improvement, and potential re-rating after asset sales.
- Pharmaceutical-focused venture capital and specialty biotech funds - backing platform/technology development and non-opioid pain management innovation.
- Long-term investors - seeking protection from generics via a patent estate extending to 2033 and potential recurring revenue from approved products or platform licensing.
- Short-term traders - exploiting historical share-price volatility around corporate news, earnings, or regulatory milestones.
- ESG-focused investors - interested in non-opioid therapeutic development aligning with social components of ESG frameworks.
- Operational strategy: recent DSUVIA divestment aimed at streamlining operations and lowering net debt load.
- IP runway: core patents and exclusivity positions reportedly extending through 2033 for certain platform elements.
- Pipeline & platform exposure: proprietary delivery systems targeting acute pain and non-opioid approaches.
- Liquidity & float: historically limited free float increases volatility and makes share ownership position-sensitive for funds.
| Holder | Approx. Shares Held | Approx. Ownership % | Position Type |
|---|---|---|---|
| The Vanguard Group, Inc. | ~3.9 million | ~5.2% | Index/Mutual Fund |
| BlackRock, Inc. | ~3.6 million | ~4.8% | Asset Manager |
| Fidelity Management & Research | ~2.7 million | ~3.6% | Active Mutual Fund |
| State Street Global Advisors | ~2.2 million | ~2.9% | Index/ETF |
| Renaissance Technologies LLC | ~1.5 million | ~2.0% | Hedge Fund/Quant |
| Insiders & Officers (aggregate) | ~9.0 million | ~12.0% | Management/Founders |
- Average daily trading volume: typically modest, amplifying price moves on news and institutional flow.
- Short interest: periodically elevated vs. float, making the ticker sensitive to squeezes or abrupt cover activity.
- Event-driven catalysts: pipeline readouts, regulatory updates, divestiture-related disclosures, and quarterly results.
- Growth/speculation: asymmetric upside if delivery platforms gain adoption or if licensing deals materialize.
- Value/turnaround: post-divestiture balance-sheet improvements can attract funds seeking de-risked small caps.
- Thematic/ESG: non-opioid pain solutions fit social impact and patient-safety objectives for certain ESG mandates.
- Income/licensing play: potential future royalty streams from platform commercialization are of interest to longer-term funds.
AcelRx Pharmaceuticals, Inc. (ACRX) - Key Investors and Their Impact on AcelRx Pharmaceuticals, Inc. (ACRX)
AcelRx's investor base is a mix of institutional holders, retail shareholders and insiders, with recent corporate actions shaping ownership and financial flexibility.- Institutional ownership: ~19.79% of shares outstanding, indicating moderate institutional interest.
- Largest institutional shareholder: a healthcare-focused mutual fund holding the single biggest institutional stake, signaling sector-specific conviction in AcelRx's strategy and product focus.
- Insider ownership: ~3%, reflecting a modest management stake that aligns some executive incentives with shareholder outcomes.
- Capital raises: In 2022, AcelRx raised $25 million via public offerings and private placements, causing dilution but providing necessary cash runway.
- Debt posture: Recent repayment of the senior loan with Oxford Finance has reduced leverage and improved the company's balance sheet profile.
| Metric | Value |
|---|---|
| Institutional Ownership | 19.79% |
| Insider Ownership | ~3% |
| 2022 Capital Raised | $25,000,000 |
| Market Capitalization | $14.58 million |
| Shares Outstanding | 16,952,000 |
| Senior Loan Status | Repaid (Oxford Finance) |
- Why institutions invest: sector expertise (healthcare-focused funds), potential upside from commercial launches or licensing, and balance-sheet improvements post-loan repayment.
- Investor impact: institutional stakes around 20% provide governance influence without full control; continued institutional interest can facilitate future capital access and partnerships.
- Risks for investors: small-cap market cap (~$14.58M) and prior dilution from the $25M 2022 raise mean potential volatility and sensitivity to operational milestones.
AcelRx Pharmaceuticals, Inc. (ACRX) - Market Impact and Investor Sentiment
AcelRx's investor base combines institutional confidence, targeted biotech venture capital, activist pressure and strategic private backers. These shareholders influence liquidity, strategic direction, R&D funding and market perception.
- Prominent healthcare-focused mutual fund: increased its stake by 5% in Q4 2024, signaling renewed confidence in management's strategic initiatives and recent commercialization efforts.
- Biotech venture capital firm: holds a 2% stake, providing financial and technical support for pain-management R&D programs.
- Activist investor: acquired a 1.5% stake in 2023 and is pushing for operational efficiency and strategic realignment to enhance shareholder value.
- Pharmaceutical industry veteran (private investor): holds a 1% stake and offers industry relationships and guidance to accelerate partner deals and commercialization.
- Family office: holds a 0.5% stake, contributing patient capital and long-term growth orientation.
- European institutional investor: holds a 0.3% stake, reflecting cross-border interest in AcelRx's proprietary pain-management technologies.
| Investor Type | Stake | Primary Influence | Timeframe / Action |
|---|---|---|---|
| Healthcare-focused mutual fund | +5% (Q4 2024 increase) | Validation of strategy; buying pressure; signal to other institutions | Q4 2024 - stake increased |
| Biotech venture capital firm | 2% | R&D support; technical collaboration potential | Ongoing holding |
| Activist investor | 1.5% | Operational reviews; push for cost discipline, strategic alternatives | Acquired stake in 2023 |
| Pharmaceutical industry veteran (private) | 1% | Strategic guidance; business development introductions | Private investment (ongoing) |
| Family office | 0.5% | Long-term capital; stable shareholder base | Ongoing holding |
| European institutional investor | 0.3% | International endorsement; potential partner relationships | Ongoing holding |
- Market Sentiment: The mutual fund's Q4 2024 increase acted as a positive catalyst - trading desks and index trackers often view such moves as confidence signals, which can reduce volatility and attract incremental institutional interest.
- R&D and Valuation: The VC's 2% stake supports continued investment into pain-management pipeline work; specialized investor backing can justify a premium on future earnings multiple if clinical progress is demonstrated.
- Governance & Efficiency: The activist's 1.5% stake raises the probability of cost optimization measures, potential asset reviews or strategic transactions intended to unlock shareholder value.
- Strategic Momentum: Industry veteran and family office stakes (1% and 0.5%) stabilize shareholder composition and enhance access to pharma networks and longer-term capital.
For historical context on ownership, mission and how AcelRx operates, see: AcelRx Pharmaceuticals, Inc. (ACRX): History, Ownership, Mission, How It Works & Makes Money
AcelRx Pharmaceuticals, Inc. (ACRX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.